UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 4, 2019

AngioDynamics, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)

000-50761 (Commission File

11-3146460 (IRS Employer Identification No.)

14 Plaza Drive Latham, New York

Number)

12110 (Zip Code)

 \square Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

(Address of Principal Executive Offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

(518) 795-1400 (Registrant's telephone number, including area code)

	☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
	□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
cha	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this upter).
	Emerging growth company \square

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 – Regulation FD Disclosure.

Presentation slides discussing AngioDynamics, Inc. ("AngioDynamics") and its fiscal second quarter ended November 30, 2018 are being furnished herewith as Exhibit 99.1. The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of AngioDynamics under the Securities Act of 1933, as amended.

Item 9.01 – Financial Statements and Exhibits.

Exhibits.

Description

Exhibit No. 99.1 Presentation dated January 4, 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC. (Registrant)

Date: January 4, 2019

By: /s/ Stephen A. Trowbridge
Name: Stephen A. Trowbridge
Title: Senior Vice President and General Counsel

AngioDynamics

Second Quarter 2019 Earnings Presentation January 4, 2019

Forward-Looking Statements

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans are statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variation statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are caution expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third par competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms a overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborator liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital mark currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integratime in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2018. AngioDynamics does relooking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tiethe European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the under consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GA EBITDAS (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income; adjusted earnings per shar analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing Ang GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management enc in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from t results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

Second Quarter 2019 Highlights

Financial Performance

- Revenue of \$91.5 million, compared to \$86.7 million a year ago. Organic revenue was \$88.7 m
- Gross Margin of 53.7%, up 440 bps year over year.
- Adjusted EPS of \$0.22, compared to \$0.17 a year ago.
- Adjusted EBITDAS of \$16.3 million, compared to \$13.3 million a year ago.
- Cash provided by operations of \$13.0 million.
- Reconfirming previous guidance on revenue, adjusted EPS, and free cash flow.
- Narrowing the gross margin expectation for the full year to between 54% and 55%.

Select Product Family Year-over-Year Sales Gro

Vascular Interventions and Therapies

Fluid Management: 7%

AngioVac[®]: 20%

• Core Peripheral: 2%

• Venous Insufficiency: (9%)

Vascular Access

Midlines: 6%

• PICCs: (5%)

Ports: 8%

Dialysis: 9%

Corporate Developments

- · RadiaDyne and BioSentry acquisitions successfully integrated and are performing in line with o
- Continued progress towards receiving FDA approval to begin our DIRECTtm NanoKnife study for
 - o Received notification from the FDA that NanoKnife will be considered a Category B IDE

Second Quarter and Year-to-Date FY 2019

\$ in thousands (except per share data)	FY2019 Q2 Results	FY2018 Q2 Results	Change	F'
y in chousanus (except per share untu)	Q2 NOOdito	Q_ NOOdito	onange	15
Revenue - Vascular Interventions and Therapies - Vascular Access - Oncology - United States - International	\$91,503 52,494 23,723 15,286 71,883 19,620	\$86,706 51,368 22,574 12,764 68,301 18,405	5.5% 2.2% 5.1% 19.8% 5.2% 6.6%	
Net Income Adjusted Net Income	\$2,140 \$8,386	\$249 \$6,298		
GAAP Earnings Per Share Non-GAAP Adjusted EPS	\$0.06 \$0.22	\$0.01 \$0.17		
Gross Margin	53.7%	49.3%		
Adjusted EBITDAS	\$16,316	\$13,335		
Free Cash Flow	\$12,225	\$9,444		
Cash	\$42,820	\$74,096*		
Debt	\$145,000	\$92,500*		

^{*} Balances reflect amounts at 5/31/2018

GAAP to Non-GA

Reconciliation of GAAP to Non-GAAP Net Incon

	Three months ended				Six months ended					
	Nover	November 30,		November 30,		Nove	mber 30,	November 30,		
Amounts in thousands	2018		2017		_	2018		2017		
	(unaudited)				(unaudited)					
Net income	\$	2,140	\$	249	:	\$	1,671	\$	214	
Amortization of intangibles		5,188		4,146			9,304		8,242	
Change in fair value of contingent consideration		244		82			256		187	
Acquisition, restructuring and other items, net (1)		2,728		4,766			7,150		7,755	
Tax effect of non-GAAP items (2)	((1,914)		(2,945)			(3,779)		(5,123)	
Adjusted net income	\$	8,386	\$	6,298	:	\$	14,602	\$	11,275	
	3						331	10.0	55	
	Three months ended				Six months ended			d		
	November 30, November 30,			November 30, No		Nov	ember 30,			
	2018 2		2017		2018			2017		
	(unaudited)				(unaudited)					
Diluted earnings per share	\$	0.06	\$	0.01		\$	0.04	\$	0.01	
Amortization of intangibles		0.14		0.11			0.24		0.22	
Change in fair value of contingent consideration		0.01		0.00			0.01		0.01	
Acquisition, restructuring and other items, net (1)		0.07		0.13			0.19		0.21	
Tax effect of non-GAAP items (2)		(0.06)		(0.08)			(0.10)		(0.15)	
Adjusted diluted earnings per share	\$	0.22	\$	0.17	:	\$	0.38	\$	0.30	
		-						90		
Adjusted diluted share count	3	38,117		37,383			38,131		37,322	

Reconciliation of Net Income to EBITDAS to

	November 30,		November 30,		Nove
	2018 2017 (unaudited)		2017		2
Amounts in thousands					
Net income	\$	2,140	\$	249	\$
Income tax expense (benefit)		591		(166)	
Interest expense, net		1,330		760	
Depreciation and amortization		6,692		5,884	
Stock-based compensation		2,591		1,966	
EBITDAS	\$	13,344	\$	8,693	
Change in fair value of contingent consideration	\$	244	\$	82	
Acquisition, restructuring and other items, net (1)		2,728		4,560	97
Adjusted EBITDAS	\$	16,316	\$	13,335	\$ 2
Per diluted share:					
EBITDAS	\$	0.35	\$	0.23	\$
Adjusted EBITDAS	\$	0.43	\$	0.36	\$

⁽¹⁾ Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impailitigation, and other items.

